Drug Trial Radar · NCT00390221
Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Jul 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
621
Actual
Start
Feb 2008
Primary completion
May 2011
Study completion Aug 2011
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Oct 19, 2006
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapses between baseline and Week 52. The secondary objectives are to determine whether DAC HYP is effective in reducing the number of new gadolinium (Gd)-enhancing lesions, reducing the number of new or newly-enlarging T2 hyperintense lesions, reducing the proportion of participants with relapses, and improving quality of life.
Conditions
- Relapsing-Remitting Multiple Sclerosis
Interventions
BIIB019 (Daclizumab High Yield Process)Biological
SC injection
PlaceboDrug
Placebo SC injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adjusted Annualized Relapse Rate Between Baseline and Week 52Time frame: Baseline through Week 52
Locations
56 sites in 8 countries. Site status is shown where the registry gives one.
Research Site
Brno, Czechia
Research Site
Olomouc, Czechia
Research Site
Pilsen, Czechia
Research Site
Teplice, Czechia
Research Site
Erlangen, Germany
Research Site
Marburg, Germany
Research Site
Osnabrück, Germany
Research Site
Regensburg, Germany
Research Site
Rostock, Germany
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Esztergom, Hungary
Research Site
Győr, Hungary
Research Site
Kecskemét, Hungary
Research Site
Miskolc, Hungary
Research Site
Nyíregyháza, Hungary
Research Site
Siófok, Hungary
Research Site
Zalaegerszeg, Hungary
Research Site
Andra-Pradeash, India
Research Site
Bangalore, India
Research Site
Chennai, India
Research Site
Kolkata, India
Research Site
Mumbai, India
Research Site
Rajasthan, India
Research Site
Visakhapatnam, India
Research Site
Bialystok, Poland
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Krakow, Poland
Research Site
Lodz, Poland
Research Site
Lublin, Poland
Research Site
Warsaw, Poland
Research Site
Kazan', Russia
Research Site
Krasnoyarsk, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Research Site
Novosibirsk, Russia
Research Site
Omsk, Russia
Research Site
Saint Petersburg, Russia
Research Site
Samara, Russia
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.